Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC(TM)) to our surgeons
MWN-AI** Summary
Smith+Nephew, a leading global medical technology company, has entered into an exclusive U.S. distribution agreement with RMR Ortho to distribute the A’TOMIC™ Nitinol Fixation System. This new addition to their Trauma, Foot & Ankle, and Hand & Wrist portfolio is designed to enhance implant integrity and patient comfort, pivotal concerns for surgeons and healthcare providers.
The A'TOMIC™ system, characterized by its unique dynamic compression properties, utilizes proprietary manufacturing techniques alongside the special properties of nitinol. It features compressive fixation implants with a wide bridge and barbed, round legs that conform to drill holes. The engineering of this system aims at stabilizing fusion, fracture, and osteotomy sites through high strength and active compression.
Scott Gunn, Vice President of U.S. Marketing for Trauma, Extremities, and Shoulder at Smith+Nephew, emphasized that this partnership enhances their fixation portfolio and provides a solution that complements existing technologies, thereby allowing Smith+Nephew to effectively engage with surgeons while addressing high-frequency fracture and arthrodesis procedures.
Joe Ritz, CEO of RMR Ortho, highlighted that partnering with Smith+Nephew marks a significant milestone for their company, aiming to broaden the availability of the A'TOMIC system across major U.S. territories. He noted that Smith+Nephew's established orthopedic framework and extensive surgeon relationships make them an ideal partner in offering reliable fixation solutions.
This collaboration aligns with Smith+Nephew’s strategy of sustainable growth and disciplined portfolio expansion, ultimately striving to improve surgical outcomes and patient care through innovative technologies. Smith+Nephew, founded in 1856, continues to operate in over 100 countries, maintaining a strong presence in the medical technology sector.
MWN-AI** Analysis
Smith+Nephew (LSE:SN, NYSE:SNN) has recently signed an exclusive distribution agreement with RMR Ortho to incorporate the innovative A'TOMIC™ Nitinol Fixation System into its portfolio. This deal is pivotal as it enhances Smith+Nephew's existing trauma, foot, and ankle offerings, improving their ability to provide advanced fixation solutions during high-frequency fracture and arthrodesis procedures. The core benefits of the A'TOMIC™ system include improved implant integrity and patient comfort, both essential factors for healthcare providers looking to enhance surgical outcomes.
From a market perspective, this collaboration positions Smith+Nephew to capitalize on an increasingly competitive orthopedic market where technological advancements drive growth. The A'TOMIC™ system’s dynamic compression capabilities and unique engineering are expected to meet the evolving demands of surgeons, which may translate into increased sales and deeper engagement with healthcare professionals. Smith+Nephew's established sales channels and relationships with surgeons are significant advantages that can foster rapid adoption of A'TOMIC™.
Investors should view this agreement as a positive signal. The partnership aligns with Smith+Nephew’s strategic focus on sustainable growth and portfolio expansion, which has been a consistent theme in their operational strategy. Furthermore, the transaction supports Smith+Nephew's strong positioning in the orthopedic segment, a market expected to witness robust growth, fueled by increasing surgical procedures and an aging population.
In light of this announcement, analysts might consider increasing their price targets for Smith+Nephew shares, subject to further developments in the uptake of the A'TOMIC™ system. However, it is essential to monitor potential risks, such as market competition and regulatory challenges, that could impact product rollout and sales. Overall, the outlook for Smith+Nephew appears favorable, bolstered by this innovative addition to their product lineup.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A’TOMIC™ Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. The system is designed to improve implant integrity and patient comfort1-6—key priorities for surgeons and healthcare systems alike.
“This partnership with RMR Ortho strengthens Smith+Nephew’s fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies,” said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder at Smith+Nephew. “The A’TOMIC Nitinol Fixation System expands our ability to participate in high-frequency fracture and arthrodesis procedures while leveraging our established Extremities and Trauma sales channel to deepen surgeon engagement. This collaboration reflects our disciplined approach to portfolio expansion and our continued focus on driving sustainable growth.”
The A’TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide compressive fixation implants featuring a wide bridge with barbed, round legs that match drill holes.1-6 The system is engineered to achieve stability of fusion, fracture and osteotomy sites through high strength and active compression.7-9
“Partnering with Smith+Nephew represents an important step forward for RMR Ortho as we continue to expand access to the A’TOMIC Nitinol Fixation System across key U.S. territories,” said Joe Ritz, CEO of RMR Ortho. “Smith+Nephew’s established presence in orthopedic extremities and trauma, deep surgeon relationships, and commercial scale make them a strong partner as we work to deliver reliable, continuously compressive fixation solutions to surgeons, hospitals, and patients.”
Media Enquiries
Gina Kamler +1 (901) 351-6991
Smith+Nephew gina.kamler@smith-nephew.com
References
- RMR Ortho. Internal Report Elastic Static Bend Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Bending Fatigue Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Static Leg Compression Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Static Axial Pull-out Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Reports. Simulated Leg Compression Testing of RMR Ortho A’TOMIC Implants.
- Dock CC, Freeman KL, Coetzee JC, McGaver RS, Giveans MR. Outcomes of Nitinol Compression Staples in Tarsometatarsal Fusion. Foot & Ankle Orthopaedics. 2020;5(3). doi:10.1177/2473011420944904
- Duerig T, Pelton A, Stöckel D. An overview of nitinol medical applications, Materials Science and Engineering: A, Volumes 273–275, 1999, Pages 149-160.
- Pelton, Alan R. et al. “Medical Uses of Nitinol.” Materials Science Forum 327-328 (2000): 63 - 70.
- Sleiman A., Bejcek C., Nestler A., Revelt N., Thuppal S., Mills A., Gardner M. The history of orthopaedic use of nitinol compression staples. Injury 2023; 54(11): 111036.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
A'TOMIC™ Trademark of RMR Ortho. Certain marks registered in US Patent and Trademark Office.
? Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. 49765 02/26
FAQ**
How does the exclusive distribution agreement with RMR Ortho for the A’TOMIC™ Nitinol Fixation System enhance Smith & Nephew Plc Ord SNNUF's competitive positioning within the Trauma, Foot & Ankle, and Hand & Wrist markets?
What specific strategies will Smith & Nephew Plc Ord SNNUF implement to deepen surgeon engagement following the addition of the A’TOMIC™ Nitinol Fixation System to its product offerings?
In what ways does the A’TOMIC™ Nitinol Fixation System align with Smith & Nephew Plc Ord SNNUF's focus on sustainable growth and portfolio expansion within the orthopedic market?
What are the potential risks and challenges associated with integrating the A’TOMIC™ Nitinol Fixation System into Smith & Nephew Plc Ord SNNUF's existing sales channels in the U.S. market?
**MWN-AI FAQ is based on asking OpenAI questions about Smith & Nephew SNATS Inc. (NYSE: SNN).
NASDAQ: SNN
SNN Trading
-1.12% G/L:
$34.38 Last:
347,571 Volume:
$34.77 Open:
